Clinical Trial

A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors

Name: A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors — clinical trial record (NCT07744763)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This trial is the first-in-human study of SYS6041, a multicenter, open-label, dose-escalation, dose-reassignment and cohort-expansion Phase I/IIa clinical study, which aims to evaluate the safety, tolerability, pharmacokinetic (PK) profile and preliminary antitumor efficacy of SYS6041 in participants with advanced solid tumors.

Trial Details

NCT Number	NCT07744763
Lead Sponsor	CSPC Megalith Biopharmaceutical Co.,Ltd.
Conditions	Advanced Solid Tumors
Enrollment	260 participants
Start Date	2025-03-28
Primary Completion	2027-03-28 (estimated)
Study Completion	2027-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-04